Wnt/β-Catenin Signaling Contributes to Paclitaxel Resistance in Bladder Cancer Cells with Cancer Stem Cell-Like Properties
Authors:
- Rocío Jiménez-GuerreroRJRocío Jiménez-Guerrero
- Alejandro Belmonte-FernándezABAlejandro Belmonte-Fernández
- M. Luz FloresMFM. Luz Flores
- Mónica González-MorenoMGMónica González-Moreno
- Begoña Pérez-ValderramaBPBegoña Pérez-Valderrama
- Francisco RomeroFRFrancisco Romero
- Miguel Á. JapónMJMiguel Á. Japón
- Carmen SáezCSCarmen Sáez
Open Access
- 31 December 2021
- journal article
- research article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 23 (1) , 450
Abstract
The Wnt/β-catenin pathway plays an important role in tumor progression and chemotherapy resistance and seems to be essential for the maintenance of cancer stem cells (CSC) in several tumor types. However, the interplay of these factors has not been fully addressed in bladder cancer. Here, our goal was to analyze the role of the Wnt/β-catenin pathway in paclitaxel resistance and to study the therapeutic efficacy of its inhibition in bladder cancer cells, as well as to determine its influence in the maintenance of the CSC-like phenotype in bladder cancer. Our results show that paclitaxel-resistant HT1197 cells have hyperactivation of the Wnt/β-catenin pathway and increased CSC-like properties compared with paclitaxel-sensitive 5637 cells. Paclitaxel sensitivity diminishes in 5637 cells after β-catenin overexpression or when they are grown as tumorspheres, enriched for the CSC-like phenotype. Additionally, downregulation of β-catenin or inhibition with XAV939 sensitizes HT1197 cells to paclitaxel. Moreover, a subset of muscle-invasive bladder carcinomas shows aberrant expression of β-catenin that associates with positive expression of the CSC marker ALDH1A1. In conclusion, we demonstrate that Wnt/β-catenin signaling contributes to paclitaxel resistance in bladder cancer cells with CSC-like properties.Keywords
Funding Information
- Instituto de Salud Carlos III (FIS-PI17/1240, FIS-PI20/1641)
- Ministerio de Economía y Competitividad (SAF2017-87358-C2-1-R and -2-R)
- Ministerio de Ciencia e Innovación (PID2020-118774RB-C21 and -C22)
- Consejería de Salud y Familias (PI-0213-2020, OH-0017-2018)
This publication has 45 references indexed in Scilit:
- Differential Effects of Drugs Targeting Cancer Stem Cell (CSC) and Non-CSC Populations on Lung Primary Tumors and MetastasisPLOS ONE, 2013
- Wnt/β-Catenin Signaling and DiseaseCell, 2012
- β-Catenin Mediates the Establishment and Drug Resistance of MLL Leukemic Stem CellsCancer Cell, 2010
- Aldehyde Dehydrogenase 1 A1–Positive Cell Population Is Enriched in Tumor-Initiating Cells and Associated with Progression of Bladder CancerCancer Epidemiology, Biomarkers & Prevention, 2010
- WNT signaling regulates self-renewal and differentiation of prostate cancer cells with stem cell characteristicsCell Research, 2009
- Differentiation of a Highly Tumorigenic Basal Cell Compartment in Urothelial CarcinomaStem Cells, 2009
- Somatic mutations of adenomatous polyposis coli gene and nuclear b‐catenin accumulation have prognostic significance in invasive urothelial carcinomas: Evidence for Wnt pathway implicationInternational Journal of Cancer, 2008
- Epigenetic Inactivation of Wnt Inhibitory Factor-1 Plays an Important Role in Bladder Cancer through Aberrant Canonical Wnt/β-Catenin Signaling PathwayClinical Cancer Research, 2006
- Wnt signalling in stem cells and cancerNature, 2005
- Prospective identification of tumorigenic breast cancer cellsProceedings of the National Academy of Sciences, 2003